Pasithea Therapeutics Corp. (NASDAQ: KTTA) has amended the clinical study protocol for its Phase 1/1b trial of PAS-004, a macrocyclic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE